Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Sangani

P1.04-32 Phase I/Ii Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (Pts) With Advanced NSCLC

Journal of Thoracic Oncology

English

Related publications

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

Journal of Thoracic Oncology

English

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

Journal of Thoracic Oncology

English

Fludarabine Combined With Radiotherapy in Patients With Locally Advanced NSCLC Lung Carcinoma: A Phase I Study

Journal of Cancer Research and Clinical Oncology

English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology

English

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

A Phase I Study of the HDM2 Antagonist SAR405838 Combined With the MEK Inhibitor Pimasertib in Patients With Advanced Solid Tumours

British Journal of Cancer

Cancer Research

Oncology

2018

English

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated With Chemotherapy

Journal of Thoracic Oncology

English

MA10.05 Effect of Early Steroids Use in Advanced NSCLC Patients Treated With Immunotherapy

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Sangani

P1.04-32 Phase I/Ii Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (Pts) With Advanced NSCLC

Related publications

MINI01.02: Response and Plasma Genotyping From Phase I/Ii Trial of Ensartinib (X-396) in Patients (Pts) With ALK+ NSCLC

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

Fludarabine Combined With Radiotherapy in Patients With Locally Advanced NSCLC Lung Carcinoma: A Phase I Study

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

A Phase I Study of the HDM2 Antagonist SAR405838 Combined With the MEK Inhibitor Pimasertib in Patients With Advanced Solid Tumours

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated With Chemotherapy

MA10.05 Effect of Early Steroids Use in Advanced NSCLC Patients Treated With Immunotherapy